Lumavex Multivitamin 5 mg; 35.7 mg; 25 mg; 65 mg; 20 mg; 5 mg; 1.67 mg; .5 mg Capsule, 30-count — NDC 85477-610-30 (Billing 85477-0610-30)
by Oncora Pharma, LLC · 30 CAPSULE in 1 BOTTLE
This is a package of 30 capsules of Lumavex Multivitamin 5 mg; 35.7 mg; 25 mg; 65 mg; 20 mg; 5 mg; 1.67 mg; .5 mg Capsule from Oncora Pharma, LLC, marketed since Oct 2025 and currently FDA-listed. It is this product's only package size.
NDC 85477-0610-30
🏷️ FDA NDC (as labeled)
85477-610-30
billing pads the product segment with a zero
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Aug 27, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
NDC database record
One package, one record: these facts belong to NDC 85477-610-30 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 85477 labeler · 610 product · 30 package
- Package marketed since
- Oct 15, 2025
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2026
- Billing quantity
- 30 EA per package
- Barcode (UPC)
- 0723587156006
- Medicaid fills, this package
- 460 prescriptions in the last four reported quarters
- FDA record last changed
- Aug 27, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
FDA NDC (as labeled)
85477-610-30
Product NDC
85477-610
11-digit billing NDC
85477061030
NCPDP billing unit
EA — each (per item)
UNII
M572600E5P, 25X51I8RD4, 68Y4CF58BV, PQ6CK8PD0R, 19F5HK2737, TLM2976OFR +2 more
UPC
0723587156006
SPL Set ID
4139742d-d091-121c-e063-6394a90a6221
Established class (EPC)
Vitamin C
Chemical class
Ascorbic Acid
DEA schedule
Non-controlled
Marketing category
UNAPPROVED DRUG OTHER
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2025-10-15
Route
ORAL
Dosage form
CAPSULE
Substance
THIAMINE HYDROCHLORIDE; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; ASCORBIC ACID; PANTOTHENIC ACID; RIBOFLAVIN; FOLIC ACID; METHYLCOBALAMIN
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
GPI-14
78120000000100
GCN Seq No
088343
GCN
58464
HICL code
050947
Ingredient (HICL)
B1/B2/B3/B5/B6/Folic/B12/Vit C
HIC1 code
C
Therapeutic class — broad (HIC1)
Electrolyte Balance/Metabolism/Nutrition
HIC2 code
C6
Therapeutic class — intermediate (HIC2)
Vitamins
HIC3 code
C6B
Therapeutic class — specific (HIC3)
Vitamin B Preparations
AHFS code
88:08.00.00
AHFS class
Vitamin B Complex
FDB label name
LUMAVEX CAPSULE
FDB brand name
Lumavex
Legend status
Q — Non-drug — dietary supplement, vitamin, medical food, or herbal preparation
Quick answers
- GSN (GCN sequence number): 088343
- GCN: 58464
- GPI-14 (Medi-Span): 78120000000100
- HICL (First Databank): 050947
- AHFS class code: 88:08.00.00
Why two NDCs?
The FDA registers this code as 85477-610-30 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 85477-0610-30. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 8, 2026
Clinical
Label name LUMAVEX CAPSULE Ingredient B1/B2/B3/B5/B6/Folic/B12/Vit C
🧪 What is this product?
Lumavex is an oral capsule containing eight B vitamins and vitamin C. The B vitamins (thiamine, riboflavin, niacinamide, pantothenic acid, pyridoxine, methylcobalamin, and folic acid) are typically used to support energy metabolism and nervous system function, while ascorbic acid (vitamin C) is commonly included in multivitamins for its role in immune and connective tissue support. This product is marketed without an approved FDA application.
Patient education
Supplement & herbal interactions
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 6, 2026
💬 Questions about Multivitamin?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | $27.21 | $816.21 / 30 capsules |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · through Q1 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 85477-0610-30 You're viewing this Main listing | 30 CAPSULE in 1 BOTTLE | 2025-10-15 | — | Active |
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Lumavex 5 mg/1; 35.7 mg/1; 25 mg/1; 65 mg/1; 20 mg/1; 5 mg/1; 1.67 mg/1; .5 mgthis 85477-0610-30 | Oncora | 30 capsules | — | — | FDA listed | — |
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
🏛️
2025
On the market since
Oct 2025
📍
2026
Currently FDA-listed
1 year listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
2 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 6, 2026
- FDA openFDA NDC Directory · synced Oct 8, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
Manufacturer & labeler
LabelerOncora Pharma, LLC
Labeler code85477
First marketedOct 2025
Product typeHuman Prescription Drug
Portfolio42 products on file
More NDCs from Oncora Pharma, LLC labeler code 85477
- Tolfyra Tolnaftate .3 g/30mL Liquid NDC 85477-331-01
- Metavex .125 mg; 1 mg; 500 mg; 425 mg; 225 mg; 135 mg Tablet NDC 85477-503-30
- Folartex Multivitamin 300 ug; 60 mg; 10 ug; 4.5 mg; 26 mg; .28 mg; 1.67 mg; .013 mg; 80 mg Tablet NDC 85477-511-30
- Vitavera 2500 [iU]/1; 30 mg; 30 mg; 400 [iU]/1; 15 [iU]/1; 1 mg; 1 mg; 13 mg; 1 mg; 1000 ug; 4 ug Tablet, Chewable NDC 85477-513-30
- Folyra Multivitamin 300 ug; 60 mg; 10 ug; 4.5 mg; 26 mg; .28 mg; 1.67 mg; .013 mg; 80 mg Tablet NDC 85477-523-30
- Virexa Vitamin C, Vitamin D3, Vitamin B1, Vitamin B6, Vitamin B12, Folic Acid, NADH, Ubiquinone 125 mg; 12.5 ug; 25 mg; 125 mg; 1.667 mg; 1 mg; 5 mg; 50 mg Tablet NDC 85477-606-30
- Lunavira Multivitamin 5 mg; 35.7 mg; 25 mg; 65 mg; 20 mg; 5 mg; 1 mg; .5 mg Capsule NDC 85477-623-30
- Bionara ULTRA Probiotic Dietary Supplement Capsules 14 410 mg; 410 mg; 410 mg; 410 mg; 25 mg; 10 mg Capsule NDC 85477-710-30
- Microvara Probiotic Dietary Supplement 217 mg; 217 mg; 217 mg; 217 mg; 217 mg; 20 mg Capsule NDC 85477-711-30
- Probentra Probiotic Dietary Supplement Capsules 14 400 mg; 400 mg; 400 mg; 400 mg; 30 mg; 12 mg Capsule NDC 85477-712-30
- LidexaGel 5% Lidocaine HCl 50 mg/g Gel NDC 85477-730-07
- Folvyris Folate, Vitamin D3 1.7 mg; .125 mg Tablet NDC 85477-823-30
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
- FDA openFDA NDC Directory · synced Oct 8, 2026
- Drugs@FDA
Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage
⏱️ Dosage and Administration
⛔ Contraindications
⚠️ Warnings
🤒 Adverse Reactions
📦 How Supplied / Storage and Handling
📦 Storage and Handling
📋 Description
📄 Other Information
⚠️ Precautions
📄 Package Label / Principal Display Panel
🎯 Indications and Usage ▾
Lumavex is a prescription multivitamin/multi-mineral dietary supplement formulated for the clinical dietary management of a subuoptimal nutritional status in patients where advanced folate and maintenance of good health is needed.
⏱️ Dosage and Administration ▾
Usual adult dosage is one to two capsule daily or as directed by a licensed medical practitioner.
⛔ Contraindications ▾
Lumavex is contraindicated in patients with a known hypersensitivity to any of the ingredients.
⚠️ Warnings ▾
WARNING If you are pregnant or nursing, ask a health care professional before using this product. Keep this product out of the reach of children.
🤒 Adverse Reactions ▾
Call your doctor about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
📦 How Supplied / Storage and Handling ▾
Lumavex capsules are supplied as clear capsules dispensed in HDPE plastic bottles of 30 count (85477-610-30).
📦 Storage and Handling ▾
STORAGE: Store at controlled room temperature 15°-30° C (59°-86° F). Keep in a cool dry place. MADE IN USA Distributed by: 888-321-2821 Oncora Pharma Dallas, TX 75161
📋 Description ▾
Lumavex is a prescription multivitamin/multimineral dietary supplement with 1mg Folic Acid.
📄 Other Information ▾
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN
⚠️ Precautions ▾
Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B 12 deficient. Folic acid in doses above 1.0 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.
📄 Package Label / Principal Display Panel ▾
label
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
Medicaid utilization & spend
📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q4 2025 – Q1 2026 · 2 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
460
Units reimbursed last 4 qtrs
13.9K
Gross reimbursed last 4 qtrs
$377.9K
Avg / prescription
$821.53
Avg / unit
$27.2070
Latest quarter Q1 2026
101Rx
Fee-for-service vs managed care ⓘ
Fee-for-service · 359 Rx Managed care · 101 Rx
State Medicaid map
Units reimbursed · per 100k residents
435435
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
Prescriptions—
Units—
Reimbursed—
🏆 Top states by units · per 100k residents
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.
Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Lumavex (this brand).
Top reported reactions
Age at onset
Reporter sex
Male · 34%
Female · 66%
Unknown · 0%
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
About this NDC listing & data coverage
Finished prescription product
Marketed without an FDA application
Listed without an FDA application
This product's marketing category indicates it is marketed without an approved FDA application (no NDA, ANDA, or BLA on file). Having an NDC does not by itself establish FDA approval — the NDC Directory is a listing system, not an approval decision. Approval-linked data such as Orange Book therapeutic-equivalence ratings therefore does not apply.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | ✓ Available |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Drug Other". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Oncora Pharma, LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Oncora Pharma, LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.